Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

- PMLiVE

Lilly/Boehringer’s diabetes combination Glyxambi debuts in US

Companieslaunch first fixed-dose of empagliflozin and linagliptin

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

Takeda spends $230m on oncology biotech deal

Buys into ImmunoGen’s antibody-drug conjugate technology

- PMLiVE

Merck KGaA supports Get Tested colorectal cancer campaign

Coincides with the first World Metastatic Colorectal Cancer Day

- PMLiVE

The Purple Agency appoints Andrew Jenkins and Terri Martin

Jenkinsjoins from FTI Strategic Communications and Martin comes from Porterhouse

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

FDA grants orphan drug status to Treeway’s ALS treatment

Amyotrophic Lateral Sclerosis drug TW001 gainsregulatory benefits

- PMLiVE

Pricing pressures preventing UK access to MenB vaccine

GlaxoSmithKline’s Bexsero will need a dramatic price cut to gain NHS entry

- PMLiVE

UCB: Patient centricity should move a business forward

Pharma may become obsolete if it does not include the patient voice, says Lode Dewulf

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links